• Mashup Score: 0

    Initiating targeted therapy for eligible patients with advanced non–small cell lung cancer (NSCLC) was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner.

    Tweet Tweets with this article
    • Initiating targeted therapy for eligible patients with advanced #Non–SmallCellLungCancer was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner at the @ASCO 2023 annual meeting. #ASCO23 https://t.co/2775jRlZVc https://t.co/GOTd8bl1gr